Pre-made Dinutuximab Beta benchmark antibody (Whole mAb, anti-ganglioside GD2 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Anti-ganglioside GD2 therapeutic antibody (Pre-made Dinutuximab Beta biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Dinutuximab (Ch14.18, tradename Unituxin) and dinutuximab beta (tradename Qarziba) are monoclonal antibodies used as a second-line treatment for children with high-risk neuroblastoma. Each antibody is made of both mouse and human components and targets glycolipid GD2, expressed on neuroblastoma cells and on normal cells of neuroectodermal origin, including the central nervous system and peripheral nerves. They differ in that dinutuximab is manufactured using mouse cells, and dinutuximab beta is manufactured using hamster cells. The dosing regime differs, and dinutuximab is given in combination with granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), while dinutuximab beta can be given alone.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-803-1mg	1mg	3090
GMP-Bios-INN-803-10mg	10mg	Inquiry
GMP-Bios-INN-803-100mg	100mg	Inquiry
GMP-Bios-INN-803-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Dinutuximab Beta Biosimilar, Whole Mab: Anti-Ganglioside Gd2 therapeutic antibody
INN Name	Dinutuximab Beta
Target	ganglioside GD2
Format	Whole mAb
Derivation	Chimeric
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	EUSA Pharma (Doylestown PA USA) / APEIRON Biologics AG (Vienna Austria) / Rentschler Biotechnologie GmbH (Laupheim Germany)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0